Compare Abeona Therapeutics Inc (ABEO) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bit Digital Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Bit Digital Inc trades at $1.63 (market cap $583.11M). The key difference: Bit Digital Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BTBT | |
|---|---|---|
Market Cap | $373.32M | $583.11M |
Sector | Health | Technology |
52-Week High | $7.23 | $4.22 |
52-Week Low | $4.17 | $1.27 |
Enterprise Value | $228.22M | $872.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BTBT trades at $1.74, up 5.45% in the past 24 hours, but faces bearish technical signals with 14 sell indicators. The company reported a net loss of $80.32 million in 2025 with a negative net income margin of -145.45%, though revenue reached $113.56 million. Recent news highlights a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase, signaling strategic moves in AI infrastructure and digital assets.
The outlook remains challenging due to persistent losses and high cash burn, but analyst consensus is 100% buy with potential from strategic investments. Key risks include execution on new ventures, competitive pressures, and reliance on financing amid negative operating cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
